Based on the key indicators related to Bristol Myers' liquidity, profitability, solvency, and operating efficiency, Bristol Myers Squibb may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Bristol Myers' Good Will is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 114.9 B in 2025, whereas Property Plant And Equipment Net is likely to drop slightly above 5.2 B in 2025. Key indicators impacting Bristol Myers' financial strength include:
Investors should never underestimate Bristol Myers' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bristol Myers' cash flow, debt, and profitability to make informed and accurate decisions about investing in Bristol Myers Squibb.
Cash And Equivalents
10.46 Billion
Bristol
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Dividends Paid
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Stock Based Compensation
Total Cashflows From Investing Activities
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Liabilities
Change To Netincome
Investments
Change Receivables
Net Borrowings
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Operating Activities
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Good Will
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Accounts Payable
Common Stock Total Equity
Short Term Investments
Capital Stock
Common Stock
Other Liab
Other Assets
Long Term Debt
Treasury Stock
Property Plant Equipment
Current Deferred Revenue
Net Tangible Assets
Total Permanent Equity
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Deferred Long Term Liab
Long Term Investments
Non Current Liabilities Other
Deferred Long Term Asset Charges
Short Long Term Debt
Cash And Equivalents
Net Invested Capital
Net Working Capital
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Research Development
Selling And Marketing Expenses
Net Income Applicable To Common Shares
Minority Interest
Net Income From Continuing Ops
Non Recurring
Non Operating Income Net Other
Tax Provision
Net Interest Income
Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Bristol Myers Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bristol Myers' financial statements are interrelated, with each one affecting the others. For example, an increase in Bristol Myers' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Bristol Myers' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myers Squibb. Check Bristol Myers' Beneish M Score to see the likelihood of Bristol Myers' management manipulating its earnings.
Bristol Myers Stock Summary
Bristol Myers competes with Agilent Technologies, Equillium, 23Andme Holding, DiaMedica Therapeutics, and Valneva SE. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 32200 people.
Foreign Associate
Mexico
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Bristol Myers Squibb. It measures of how well Bristol is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Bristol Myers brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Bristol had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Bristol Myers has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.
Bristol Myers Squibb is rated fifth in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Bristol Myers' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.
Bristol Myers' Earnings Breakdown by Geography
Bristol Myers Squibb Systematic Risk
Bristol Myers' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bristol Myers volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Bristol Myers Squibb correlated with the market. If Beta is less than 0 Bristol Myers generally moves in the opposite direction as compared to the market. If Bristol Myers Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bristol Myers Squibb is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bristol Myers is generally in the same direction as the market. If Beta > 1 Bristol Myers moves generally in the same direction as, but more than the movement of the benchmark.
Bristol Myers Thematic Clasifications
Bristol Myers Squibb is part of Compulsion investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol
This theme covers Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. Get More Thematic Ideas
Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bristol Myers growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Bristol Myers help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bristol Myers Squibb. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bristol Myers Squibb based on widely used predictive technical indicators. In general, we focus on analyzing Bristol Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bristol Myers's daily price indicators and compare them against related drivers.
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.